🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Functional tests tries multiple drugs on a patient's own tumor cells to find the best treatment. In clinical trials currently underway, Pangea Biomed's ENLIGHT helps physicians assemble the shortlist of drugs for functional testing, making optimal use of the available tissue.

Join our COO Emmanuel Elalouf later this week at #BIOEuropeSpring in Barcelona, Spain. You can get in touch with Emmanuel through  [email protected]

Congratulations to Pangea Biomed advisory board member Dr. Lillian Siu on being selected as President-Elect of the American Association for Cancer Research! Lillian - you are a source of inspiration, and we are so proud to have you on our advisory board!

A new study led by Sima Lev - Professor at Weizmann Institute, together with Pangea Biomed cofounders @NCIEytanRuppin and Eyal Gottlieb, sheds light on mechanisms of cell death in cancer. Congratulations Sima, Eyal and Eytan! #CancerResearch #PrecisionOncology

It’s an honor that ENLIGHT has earned the attention of Fast Company and is being celebrated on this year’s World Changing Ideas list. It is our mission to bring effective precision oncology to cancer patients and improve oncology drug development. Follow us at Pangea Biomed.

Don't miss the opportunity to meet Ranit Aharonov and Gal Dinstag at ASCO! #Biotech #Cancer #Oncology #ASCO24 #PrecisionMedicine

Still not too late to meet Ranit Aharonov and Gal Dinstag at ASCO!

Tue and Wed starting at 6:40pm, Pangea CTO, Ranit Aharonov , and Researcher, Omer Tirosh will be presenting at the EACR Conference in relation to our ENLIGHT tech and SCOT, a novel method for testing response biomarkers before interventional clinical data is available

We’ve launched a new series of short videos on ENLIGHT. Watch the first one to learn more about Pangea Biomed's technology and how it can offer cancer patients effective treatment options.

The Pangea Biomed team was at #ASCO24, #BIO2024 Convention, and #EACR24 conference, with 7 posters! Ranit Aharonov , Emmanuel Elalouf , Gal Dinstag , and Omer Tirosh presented Pangea and our ENLIGHT platform as well as SCOT - a novel method for testing predictive biomarkers.

Pancreatic cancer has a 5-year survival rate of just 3% after it spreads. Read how 12-year pancreatic cancer survivor, Steven Merlin, beat the odds as a result of a personalized medicine plan and participation in a clinical trial in PanCAN : bit.ly/44PIvZm

Our first major work on #DigitalPathology is now on Nature Cancer. Thanks go to our wonderful collaborators at National Cancer Institute and Biological Data Science Institute, and primarily Danh-Tai Hoang, @NCIEytanRuppin and @NCIKenAldape! Hoping this work will advance digital pathology-based #PrecisionOncology

A PDF copy of the ENLIGHT-DeepPT paper in Nature Cancer is available here: rdcu.be/dMB0u

To beat cancer, we must all join forces! Very proud to be part of the #LiquidBX consortium, working with other innovative companies and research labs to push the boundaries of liquid biopsy technologies. Kudos to Israel Innovation Authority for providing the funding to realize this vision.

Tzivia, our wonderful clinical operations manager, shared a moving story explaining her devotion to the fight against cancer. We all lost loved ones to cancer, but together we will eventually defeat this terrible disease! #PrecisionOncology #CancerResearch #CancerAwareness

Proud and excited to welcome @NCIKenAldape to our Scientific Advisory Board. Our ongoing collaboration with the National Cancer Institute (NCI) lab of pathology will surely benefit from Ken's deeper involvement in our broader research activities.

Our collaborators at the NCI are pushing the boundaries of digital pathology again with a new work on DP-derived spatial gene expression analysis. Cannot wait to see how this new method could improve our own ENLIGHT predictions!

It's an honor to work alongside the amazing researchers of OHSU Knight Cancer Institute to study the basis of cancer drug resistance and response.

Great to make it to this list - thank you, Fast Company, for the recognition!

What if AI could revolutionize both cancer treatment and drug development? Join me at #PMWC2025 to learn how Pangea Biomed's ENLIGHT platform is doing just that. Oncology Applications (Track 3), February 5 at 3:30pm #PrecisionMedicine #Oncology #Biomarkers #AI Precision Medicine World Conference